Blasenkarzinom – Update

Goebell PJ, Knowles MA (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28(4):409–428 Hoffmann AC,Wild P,Leicht C et al (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8):628–636 Nawroth R, Hartmann A, Wild P et al (2010) EMMPRIN (CD147): A prognostic and potentially therapeutic marker in urothelial cancer. Pathologe 31(Suppl 2):251–254 Sidhu SS, Nawroth R, Retz M et al (2010) EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 29:4145–4156 Golshani R, Lopez L, Estrella V et al (2008) Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68(2):483–491 Lokeshwar VB, Estrella V, Lopez L et al (2006) HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 66(23):11219–11227 Lokeshwar VB, Gomez P, Kramer M et al (2008) Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem 283(43):29215–29227 Girish KS, Kemparaju K, Nagaraju S et al (2009) Hyaluronidase inhibitors: a biological and therapeutic perspective. Curr Med Chem 16(18):2261–2288 Kramer MW, Golshani R, Merseburger AS et al (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57(1):86–93 Rink M, Chun FK, Minner S et al (2010) Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (Epub ahead of print) Brunner A, Prelog M, Verdorfer I et al (2008) EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 61(3):307–310 Heck MM, Gschwend JE, Retz M (2010) Update on chemotherapy for bladder cancer. Urologe A 49(10):1294–1300 Engelman JA (2009) Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562 Bamias A et al (1991) Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma. Cancer Res 51(2):724–728 Bamias A, Keane P, Krausz T et al (1993) Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer 54(6):899–903 Pfost B, Seidl C, Autenrieth M et al (2009) Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 50(10):1700–1708 Huang B, Zhao J, Unkeless JC et al (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2):218–224 Conroy H, Marshall NA, Mills KH (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27(2):168–180 Schulz WA (2006) Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119(7):1513–1518